The estimated Net Worth of Brendan Smith is at least $11 Tisíc dollars as of 18 February 2023. Brendan Smith owns over 3,825 units of Telesis Bio Inc stock worth over $10,989 and over the last 4 years Brendan sold TBIO stock worth over $0.
Brendan has made over 2 trades of the Telesis Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Brendan exercised 3,825 units of TBIO stock worth $6,503 on 18 February 2023.
The largest trade Brendan's ever made was exercising 3,825 units of Telesis Bio Inc stock on 18 February 2023 worth over $6,503. On average, Brendan trades about 947 units every 16 days since 2021. As of 18 February 2023 Brendan still owns at least 6,464 units of Telesis Bio Inc stock.
You can see the complete history of Brendan Smith stock trades at the bottom of the page.
Brendan's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON, MA, 02127.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk a Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: